🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

ImmunityBio clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK, Canada, India and Mexico registers with ImmunityBio as lead sponsor. Synced 27 Sep 2026
15Current trials
6Recruiting now
22Drugs in these trials
5Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

ImmunityBio is the lead sponsor of 15 current clinical trials in our USA, UK, Canada, India and Mexico registers. 6 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are PD-L1 t-haNK, Anktiva and Cyclophosphamide. The most-studied condition is Long COVID.

ClinicalTrials.gov trials by status

  • Recruiting640%
  • Not yet open17%
  • Active, closed853%

Trials by phase

  • Phase 2640%
  • Phase 1427%
  • Phase 1/2213%
  • Phase 317%
  • Observational17%
  • Phase 2/317%
01

Clinical trials sponsored by ImmunityBio

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NCT06745908 · ClinicalTrials.gov ↗ · NSCLC Stage IV
Phase 3 Recruiting 2025-10 UK, USA, Canada
A Study to Assess Anktiva in Patients With Long Covid-19.
NCT07108036 · ClinicalTrials.gov ↗ · Long COVID
Phase 2 Recruiting 2025-11 USA
A Study to Examine Anktiva for the Treatment of COVID-19.
NCT07123727 · ClinicalTrials.gov ↗ · Long COVID, Long COVID Syndrome, Long Covid 19
Drug: Anktiva
Phase 2 Recruiting 2025-09 USA
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
NCT05618925 · ClinicalTrials.gov ↗ · Non Hodgkin's Lymphoma Refractory/Relapsed
Phase 1 Recruiting 2025-08 USA
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963 · ClinicalTrials.gov ↗ · NMIBC
Phase 1/2 Recruiting 2025-10 USA
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
NCT06710288 · ClinicalTrials.gov ↗ · Platinum-resistant Ovarian Cancer
Phase 2 Recruiting 2024-11 USA
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
NCT07217496 · ClinicalTrials.gov ↗ · Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Phase 1 Not yet open 2026-12 USA
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734 · Non-muscle Invasive Bladder Cancer
Phase 1/2 Active, closed 2014-07 USA, India, Mexico
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT05981131 · Non Muscle Invasive Bladder Cancer
Observational Active, closed 2023-08 USA
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
NCT06061809 · Glioblastoma
Phase 2 Active, closed 2024-08 USA
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT04898543 · ClinicalTrials.gov ↗ · Metastatic Solid Tumor
Phase 1 Active, closed 2021-06 USA
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma
Phase 2 Active, closed 2018-12 USA
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT04390399 · ClinicalTrials.gov ↗ · Pancreatic Cancer
Phase 2 Active, closed 2020-07 USA
IBRX-042 In Participants With HPV-Associated Tumors
NCT05976828 · ClinicalTrials.gov ↗ · HPV-Related Carcinoma
Phase 1 Active, closed 2024-06 USA
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
NCT03022825 · ClinicalTrials.gov ↗ · Bladder Cancer
Phase 2/3 Active, closed 2017-06 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in ImmunityBio trials

22 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in ImmunityBio trials

21 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA156
Clinical trials in UK11
Clinical trials in Canada11
Clinical trials in India10
Clinical trials in Mexico10

A trial with sites in more than one country appears in each of those registers.

05

Questions about ImmunityBio trials

How many clinical trials does ImmunityBio sponsor?

ImmunityBio is the lead sponsor of 15 current trials on ClinicalTrials.gov in our USA, UK, Canada, India and Mexico registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are ImmunityBio trials recruiting?

Yes. 6 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is ImmunityBio testing?

Its current trials name 22 drugs and biologicals as interventions. The most frequent are PD-L1 t-haNK (3), Anktiva (2), Cyclophosphamide (2), Docetaxel (2) and Gemcitabine (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.